Anti-ACADL/LCAD antibody (ab129711)
Key features and details
- Rabbit polyclonal to ACADL/LCAD
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-ACADL/LCAD antibody
See all ACADL/LCAD primary antibodies -
Description
Rabbit polyclonal to ACADL/LCAD -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide corresponding to Human ACADL/LCAD.
-
Positive control
- Rat kidney tissue lysate, Mouse 3T3 cell lysate and Jurkat whole cell lysate (ab7899)
-
General notes
This product is manufactured by BioVision, an Abcam company and was previously called 3139 ACADL Antibody. 3139-100 is the same size as the 100 µg size of ab129711.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.20
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 69% PBS, 30% Glycerol (glycerin, glycerine), 0.5% BSA, 0.15% EDTA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab129711 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB |
Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 47 kDa.
|
| Notes |
|---|
|
WB
Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 47 kDa. |
Target
-
Pathway
Lipid metabolism; mitochondrial fatty acid beta-oxidation. -
Involvement in disease
Defects in ACADL are a cause of acyl-CoA dehydrogenase very long-chain deficiency (ACADVLD) [MIM:201475]. An inborn error of mitochondrial fatty acid beta-oxidation which leads to impaired long-chain fatty acid beta-oxidation. It is clinically heterogeneous, with three major phenotypes: a severe childhood form characterized by early onset, high mortality and high incidence of cardiomyopathy; a milder childhood form with later onset, characterized by hypoketotic hypoglycemia, low mortality and rare cardiomyopathy; an adult form, with isolated skeletal muscle involvement, rhabdomyolysis and myoglobinuria, usually triggered by exercise or fasting. -
Sequence similarities
Belongs to the acyl-CoA dehydrogenase family. -
Cellular localization
Mitochondrion matrix. - Information by UniProt
-
Database links
- Entrez Gene: 33 Human
- Entrez Gene: 11363 Mouse
- Entrez Gene: 25287 Rat
- Omim: 609576 Human
- SwissProt: P28330 Human
- SwissProt: P51174 Mouse
- SwissProt: P15650 Rat
- Unigene: 471277 Human
see all -
Alternative names
- ACAD4 antibody
- ACADL antibody
- ACADL_HUMAN antibody
see all
Images
-
Western blot - Anti-ACADL/LCAD antibody (ab129711)All lanes : Anti-ACADL/LCAD antibody (ab129711) at 4 µg/ml
Lane 1 : Rat
kidney tissue lysate
Lane 2 : Mouse 3T3
cell lysate
Lanes 3-4 : Jurkat cell lysate
Predicted band size: 47 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab129711 has been referenced in 8 publications.
- Yu Y et al. Exercise-Generated β-Aminoisobutyric Acid (BAIBA) Reduces Cardiomyocyte Metabolic Stress and Apoptosis Caused by Mitochondrial Dysfunction Through the miR-208b/AMPK Pathway. Front Cardiovasc Med 9:803510 (2022). PubMed: 35282369
- Gopal K et al. FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity. Cell Rep 35:108935 (2021). PubMed: 33826891
- Chella Krishnan K et al. Sex-specific genetic regulation of adipose mitochondria and metabolic syndrome by Ndufv2. Nat Metab 3:1552-1568 (2021). PubMed: 34697471
- Chen Y et al. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice. Br J Pharmacol 177:2286-2302 (2020). PubMed: 31971610
- Karwi QG et al. Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction. Cardiovasc Diabetol 18:1 (2019). PubMed: 30626440
- Karwi QG et al. Weight loss enhances cardiac energy metabolism and function in heart failure associated with obesity. Diabetes Obes Metab N/A:N/A (2019). PubMed: 31050157
- Verma S et al. Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. JACC Basic Transl Sci 3:575-587 (2018). PubMed: 30456329
- Fukushima A et al. Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism. JCI Insight 3:N/A (2018). PubMed: 29769443